ANAL CANCER: AN EXAMINATION OF RADIOTHERAPY STRATEGIES

作者：Glynne Jones Rob^*; Lim Faye

来源：International Journal of Radiation Oncology, Biology, Physics, 2011, 79(5): 1290-1301.

DOI：10.1016/j.ijrobp.2010.10.017

The Radiation Therapy Oncology Group 9811, ACCORD-03, and ACT II Phase III trials in anal cancer showed no benefit for cisplatin-based induction and maintenance chemotherapy, or radiation dose-escalation > 59 Gy. This review examines the efficacy and toxicity of chemoradiation (CRT) in anal cancer, and discusses potential alternative radiotherapy strategies. The evidence for the review was compiled from randomized and nonrandomized trials of radiation therapy and CRT. A total of 103 retrospective/observational studies, 4 Phase I/II studies, 16 Phase II prospective studies, 2 randomized Phase II studies, and 6 Phase HI trials of radiotherapy or chemoradiation were identified. There are no meta-analyses based on individual patient data.
A "one-size-fits-all" approach for all stages of anal cancer is inappropriate. Early T1 tumors are probably currently overtreated, whereas T3/T4 lesions might merit escalation of treatment. Intensity-modulated radiotherapy or the integration of biological therapy may play a role in future.

• 出版日期2011-4-1